

Analysis of electronic health record data of hepatitis B virus (HBV) patients in primary care: hepatocellular carcinoma (HCC) risk associated with socioeconomic deprivation and reduced by statins.

Cori Campbell^{1,2}, Tingyan Wang^{1,2}, Iain Gillespie³,
Eleanor Barnes^{2,4}, Philippa C Matthews^{2,5,6,7}

¹ Nuffield Department of Medicine, University of Oxford, Oxford, UK

² NIHR Oxford Biomedical Research Centre, Oxford, UK

³ GSK, Stevenage, UK

⁴ Department of Hepatology, Oxford University Hospitals, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU

⁵ The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK

⁶ Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT, UK

⁷ Department of Infectious Diseases, University College London Hospital, Euston Road, London NW1 2BU, UK

Corresponding author: philippa.matthews@crick.ac.uk

KEY WORDS

hepatitis B virus, epidemiology, liver cancer, statins, electronic health records, big data, viral hepatitis elimination

Contact information (corresponding author):

Full name: Philippa C. Matthews
Address: 1 Midland Rd, London, NW1 1AT
Phone number: +44 (0)20 379 65570
E-mail address: philippa.matthews@crick.ac.uk

List of abbreviations:

Abbreviation	Definition
95CI	95% confidence interval
aHR	Adjusted Hazards Ration
ALT	Alanine aminotransferase
AST	Aspartate transaminase
BMI	Body mass index
CHB	Chronic hepatitis B virus infection
EHR	Electronic health record
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HES	Hospital episode statistics
HIC	Health Informatics Collaborative
ICD	International Classification of Disease
IQR	Interquartile range
MICE	Multiple imputation by chained equations
NA	Nucleoside analogue
NCRAS	National Cancer Registration Analysis Service
NSAID	Non-steroidal anti-inflammatory drug
ONS	Office for National Statistics
Plt	Platelet
PPI	Proton pump inhibitor
SD	Standard deviation
SNOMED	Systemised Nomenclature of Medicine
T2DM	Type 2 diabetes mellitus
UK	United Kingdom
VL	Viral load
WHO	World Health Organisation

Financial support:

PCM is funded by Wellcome (grant ref 110110/Z/15/Z), UCLH NIHR Biomedical Research Centre and the Francis Crick Institute. CC's doctoral project is jointly funded by the Nuffield Department of Medicine, University of Oxford and by GlaxoSmithKline. EB is funded by the Oxford NIHR Biomedical Research Centre and is an NIHR Senior Investigator. The views expressed in this article are those of the author and not necessarily those of the NHS or the NIHR. PCM, EB and CC are

supported by the DeLIVER program “The Early Detection of Hepatocellular Liver Cancer” project is funded by Cancer Research UK (Early Detection Programme Award, grant reference: C30358/A29725). EB, TW, CC and PCM acknowledge support from the NIHR Health Informatics Collaborative.

ABSTRACT

Background: We set out to characterise chronic Hepatitis B (CHB) in the primary care population in England and investigate risk factors for progression to hepatocellular carcinoma (HCC).

Methods: We identified 8039 individuals with CHB in individuals aged ≥ 18 years between 1999-2019 in the English primary care database QResearch. HCC risk factors were investigated using Cox proportional hazards modelling.

Findings: Most of those living with CHB were males (60%) of non-White ethnicity (>70%), and a high proportion were in the most deprived Townsend deprivation quintile (44%). Among 7029 individuals with longitudinal data, 161 HCC cases occurred. Increased HCC hazards significantly associated with male sex (adjusted hazards ratio (aHR) 3.44, 95% Confidence Interval (95CI) 2.07-5.73), older age (for age groups 56-55 and ≥ 66 years of age, compared to 26-35 years, aHRs 7.52 (95CI 4.14-13.67) and 11.89 (95CI 6.26-22.60) respectively), socioeconomic deprivation (aHR for fifth Townsend deprivation quintile 1.69, 95CI 1.01-2.84, compared to third), Caribbean ethnicity (aHR 3.32, 95CI 1.43-7.71, compared to White ethnicity), ascites (aHR 1.85, 95CI 1.02-3.36), cirrhosis (aHR 6.52, 95CI 4.54-9.37) and peptic ulcer disease (aHR 2.20, 95CI 1.39-3.49). Reduced HCC hazards were associated with statin use (aHR 0.47, 95CI 0.22-0.99).

Interpretation: Targeting resources at vulnerable groups, and addressing modifiable risk factors is essential to improve CHB outcomes, and to support progress towards international goals for the elimination of hepatitis infection as a public health threat.

Funding: Wellcome (grant ref 110110/Z/15/Z), UCLH NIHR Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, GlaxoSmithKline, NIHR Health Informatics Collaborative, Cancer Research UK.

Research in context

Evidence before this study:

THE CHB population in England has not been well described. Hepatitis B virus (HBV) reports from the UK Health Security Agency (UHSA) have not previously reported chronic HBV (CHB) prevalence stratified by relevant subgroups, including ethnicity and socioeconomic status. The burdens of comorbid diseases in this population have also not been characterised. Furthermore, risk factors for the progression of CHB to hepatocellular carcinoma (HCC) have previously been identified largely in homogenous patient samples which may not be widely generalisable. Therefore, risk factors identified in previously published studies require validation in diverse multi-ethnic cohorts. Characterisation of CHB and investigation of novel risk factors for HCC is warranted in a large data source which contains parameters for a large percentage of the population which are collected in a systematic and wide-scale manner in order to improve generalisation of findings.

Added value of this study:

We have characterised the largest cohort of CHB individuals in the UK to date, using the QResearch primary care electronic health record database, and describing the demographics and burdens of comorbid disease in the population. This is novel and has not previously been done in a large socioeconomically and ethnically diverse patient sample. We have also analysed risk factors for HCC in the cohort, both validating previously reported factors and investigating novel factors.

Implications of all the available evidence:

The findings of this study have important implications for CHB prevention, clinical management, and resource planning. Our detailed description of the demographics and disease profile of the CHB population in the UK may facilitate the targeting of health and prevention resources. Findings concerning HCC risk factors have implications for the clinical management of CHB in order to reduce the risk of progression to HCC.

INTRODUCTORY STATEMENT

The 2022 Global Burden of Disease analysis of hepatitis B virus (HBV) epidemiology estimates that >300 million people live with chronic infection worldwide (1). Through its progression to inflammatory liver disease, cirrhosis and primary liver cancer (hepatocellular carcinoma (HCC)), chronic hepatitis B (CHB) accounts for substantial morbidity and mortality, being the leading global cause of HCC death (2), and the third largest cause of cirrhosis death (1). Age-standardised death rates have remained constant or increased for HCC and cirrhosis, respectively, and the total number of HBV-attributable deaths has increased worldwide over recent decades (3). International targets calling for the elimination of HBV infection as a public health threat by the year 2030 have been set (4), with recent recognition and investment into the early detection and treatment of HCC to reduce morbidity and mortality (5). Meeting elimination targets relies on a clear understanding of the epidemiology of infection and associated liver disease in order to target resources and interventions to high-risk groups, and to benchmark progress.

CHB prevalence has not been robustly estimated in many settings, including the UK (6), and groups at the highest risk of morbidity and mortality have not been well characterised. Furthermore, even in well-defined CHB populations, treatment coverage and eligibility are often unreported. Regional HBV reports from UK public health services (UK Health Security Agency, previously Public Health England) have included neither overall estimates of the proportion of CHB individuals receiving antiviral treatment, nor estimates stratified by relevant subgroups such as age, sex and ethnicity (6–10).

There has been increasing interest in identifying risk factors for progression of CHB to cirrhosis, HCC and other endpoints (11). Age, sex, viral load and viral genotype are recognised determinants of HCC risk (12–18), and recent studies have reported associations between HCC and various comorbidities, including type 2 diabetes mellitus (T2DM) and hypertension (11). Existing risk scores, including PAGE-B (19), REACH-B (20,21), GAG-HCC (22,23) and CU-HCC (24–26), use such risk factors to predict HCC. However, few cohorts have been characterised in European countries and/or in ethnically diverse populations, to validate or inform scoring approaches.

Studies based on electronic health records (EHRs) enable characterisation of large retrospective cohorts, thus enhancing statistical power, and identifying a study sample that is more representative of the whole disease population compared to clinical trials. Such databases often have longitudinal follow-up, with exposures and outcomes ascertained over time. EHR databases can often be linked to other registries (such as national cancer registries and vital statistics), allowing for identification of relevant endpoints.

Given the substantial evidence gaps concerning HBV epidemiology, disease burden and risk factors for progression to HCC, we set out with two aims (i) to characterise a CHB cohort collating data from a large-scale primary care database in England (27), and (ii) to investigate risk factors for progression to HCC.

PATIENTS AND METHODS

Data source and study population/design

We used data from the England primary care database QResearch (version 45), which contains >35 million patient records from >1800 individual practices (28). QResearch was established in 2002 and contains anonymised individual-level patient EHRs. Data are collected prospectively and are linked to hospital episode statistics (HES), National Cancer Registration Analysis Service (NCRAS) and Office for National Statistics (ONS) mortality data.

We first identified individuals from the QResearch database between 01 January 1999 and 31 December 2019 who were age ≥ 18 years and had a record of CHB based on a diagnostic Systemised Nomenclature of Medicine (SNOMED)/Read or International Classification of Disease (ICD) code, or who had a history of ≥ 1 hepatitis B surface antigen (HBsAg) or HBV DNA viral load (VL) measurement. From this sample we then selected patients for inclusion in our cohort who (at any time between 01 January 1999 and 31 December 2019) were aged ≥ 18 years, and has confirmed CHB. Patients were identified as having CHB if they met any one of the following conditions: (i) record of a diagnostic SNOMED/Read code indicating CHB; (ii) record of a diagnostic ICD-9 or -10 code indicating CHB, and/or; (iii) Presence of HBsAg or VL on at least two recordings ≥ 6 months apart (**Supplementary Figure 1**).

Covariate selection and ascertainment

We identified relevant covariates for extraction *a priori* based on previous literature (11,19,21–26,29) and clinical relevance. Lifestyle factors, demographics and relevant numeric biomarkers were characterised from relevant SNOMED/Read codes. Comorbidities were characterised from relevant SNOMED/Read and ICD-9 and -10 codes. Ethnicity is categorised in QResearch as per 2011 census categories (30). Townsend Deprivation quintile is available as a measure of socioeconomic status in QResearch. Body mass index (BMI, kg/m²) was categorised (underweight, <18.5 kg/m²; healthy weight, 18.5-24.9 kg/m²; overweight, 25.0-29.9 kg/m²; obese, ≥ 30 kg/m²) based on World Health Organization (WHO) categories (31). Covariate measurements made within ±3 years of earliest CHB diagnosis and before HCC diagnosis were used as proxy baseline measurements. Where patients had >1 measurement taken within 3 years of the earliest CHB diagnosis, measurements taken closest to diagnosis date were used.

Outcome ascertainment

Our primary endpoint of interest was HCC. HCC was ascertained via identification of patients with relevant SNOMED/Read or ICD codes corresponding to HCC, and by linkage of the cohort to National Cancer Registry data (32,33). In order to maximise outcome ascertainment, we used a broad definition for HCC including multiple codes relevant to HCC (**Supplementary Table 1**). We performed sensitivity analysis (further details below) whereby all patients with non-HCC neoplasms were excluded, to investigate robustness of main analysis using our broad HCC definition. A tabulation of HCC cases across source of diagnosis is depicted in **Supplementary Table 2**.

Follow-up

Earliest date of CHB diagnosis was regarded as cohort entry and initiation of follow-up for each patient. For patients who developed HCC, date of HCC diagnosis was regarded as the end of follow-up. For patients who did not develop HCC (i.e., patients who were censored), follow-up ended at patient cohort exit date (either due to leaving their general practice and switching to a practice which does not contribute to QResearch, or death) or 31 December 2019, whichever occurred earlier. Patients in whom database exit date preceded or was equal to first recorded CHB diagnosis

date (n = 1010) whereby follow-up time ≤ 0 years were excluded from longitudinal analysis.

In some patients, HCC diagnosis date or cohort exit date preceded or was equal to CHB diagnosis date (**Supplementary Table 3**). Data from these patients were excluded from analyses of HCC risk factors.

Statistical analysis

Statistical analyses were carried out in R (version 4.1.0). Baseline characteristics were summarised for all CHB patients (regardless of length of follow-up) using descriptive statistics. Means and standard deviations (SDs) or medians and interquartile ranges (IQRs) were presented for continuous measures, and were compared using *t* or Wilcoxon rank-sum tests, respectively. Patient counts and percentages were presented for continuous and binary variables, and were compared using chi-squared or Fisher's exact tests.

Univariable and multivariable Cox proportional hazards models were used to investigate risk factors for progression of CHB to HCC. Variables were included in the multivariable model based on significance of univariable associations (where *P* ≤ 0.1) and/or based on biological/clinical relevance and previous literature (11,19,21–26,29). A previous meta-analysis we undertook to investigate risk factors for HCC in CHB was also used to inform variable selection (11).

Continuous laboratory parameters which were right-skewed were transformed with a natural logarithm for inclusion in multivariable models. Laboratory parameters were divided into quintiles for inclusion in multivariable models. Means and SDs for log AST, log alanine transaminase (ALT) and platelet count (Plt) quintiles are presented in supplement (**Supplementary Table 4**). Hazard ratios and 95% confidence intervals (95% CI) were reported for Cox proportional hazards model outputs. Analysis on the imputed dataset was used for main models.

Handling of missing data

Values were missing for Townsend Deprivation Quintile, ethnicity, alcohol consumption, cigarette consumption, BMI, Plt, ALT measurement, aspartate

transaminase (AST) measurement, Hepatitis B surface antigen (HBsAg), and HBV viral load (VL). Missing data are described further in **Supplementary Table 5**.

Multiple imputation by chained equations (MICE) was used to impute missing data across patient characteristics. The assumption of missing at random was made for imputed variables. This is in accordance with previous handling of missing data in cohorts utilising QResearch data (34–37), and current recommendations for imputation of missing data (38). Characteristics with >90% missingness were not imputed. Ten imputed datasets were generated, and results from univariable and multivariable Cox proportional hazards models from each dataset were pooled according to Rubin's rules (39,40).

Sensitivity analyses

To test robustness of our main model, three sensitivity analyses were performed (**Supplementary Table 6**), as follows (i) main results model fit to complete-case cohort subset (i.e. the subset of patients with completeness for all variables); (ii) exclusion of patients with history of non-HCC neoplasms (presented in **Supplementary Table 7**) to control for unmeasured outcome misclassification whereby secondary liver cancer has been misclassified as primary HCC, and; (iii) addition of ALT, AST and Plt in the main model fit to the imputed dataset, as the percentage of missingness in these exposures was too high for them to be included in main analysis.

RESULTS

Individuals with CHB are under-represented in primary care records

We identified 8039 CHB patients in the QResearch database between 1999 and 2019 from a database-wide denominator of ~35 million individuals, which translates to a CHB prevalence of 0.023%. This is an order of magnitude less than current estimates for CHB prevalence in the UK, of 0.27% to 0.73% (41) Thus we have only had access to a dataset representing a fraction of all CHB cases. This discrepancy highlights under-diagnosis of HBV infection, and poor linkage of data between specialist care services and primary care.

The majority of patients with CHB were male, of non-white ethnicity, in the fourth and fifth (most deprived) Townsend deprivation quintiles, and not receiving treatment

Most of the adults represented in this study were identified by a SNOMED/Read or ICD CHB diagnostic code (7856/8039, 97.7%), with a remaining 2.3% (252/8039) identified by HBsAg and/or VL measurements (in the absence of a diagnostic code) (**Table 1**). Median follow-up duration was 3.87 years (IQR 6.30 years), with differential follow-up between individuals who developed HCC (median follow-up 1.47 years, IQR 5.13 years) and those who did not (median follow-up duration 3.93 years, IQR 6.28 years). Mean age at baseline was 38.3 years (SD 11.6 years), and at baseline >75% were ≤45 years of age. The majority were male (4856/8039, 60.4%).

Black Africans represented 25.4% of individuals, with 12.9% of Chinese ethnicity, 5.9% of Pakistani ethnicity, 3.0% of Indian ethnicity and 28.4% of White ethnicity (**Table 1**). Proportions of Black and ethnic minorities in our CHB cohort were greater than those in both the wider QResearch database (42) and general English population (43) (**Figure 2**).

At baseline, most (88.0%) of patients had no record of antiviral treatment. Within 1, 2, 3 and ≥ 4 years of CHB diagnoses, cumulatively 2.7%, 4.0 %, 5.0% and 10.1% of patients had record of antiviral treatment initiation, respectively.

Cohort characteristics stratified by Townsend deprivation quintile are presented in **Table 2**. Age and sex associated significantly with Townsend deprivation quintile whereby mean ages were younger ($P < 0.001$) and proportions of males were higher ($P = 0.021$) in more deprived quintiles. Ethnicity significantly differed across quintiles ($P < 0.001$) whereby the proportions of Bangladeshi and Black African ethnicity patients increased with increasing deprivation and the proportion of White and Chinese patients decreased. Alcohol and cigarette consumption were significantly associated with Townsend deprivation quintile ($P < 0.001$ and $P = 0.04$, respectively), but no obvious trends were apparent. The only comorbidities differing significantly in prevalence across quintiles were cerebrovascular disease, peptic ulcer disease and non-HCC neoplasms. Associations of antidiabetic drug, antihypertensive, NSAID and statin use with Townsend Deprivation Quintile were nonsignificant.

Prevalence of diabetes and hypertension in adults with CHB was higher than in the general population

Baseline prevalence of T2DM and hypertension were 8.9% and 15.3%, respectively. This differs from the prevalence of T2DM and hypertension in the wider QResearch database of <8% and <3%, respectively (44). Prevalence of other comorbidities (including congestive heart failure, chronic kidney disease, alcohol-related liver disease, ascites, autoimmune hepatitis, cerebrovascular disease, end-stage liver disease, ischaemic heart disease, non-alcoholic fatty liver disease and peptic ulcer disease; **Table 1**) ranged from 0.1% to 5%. Baseline cirrhosis is difficult to define from primary care EHR due to lack of relevant laboratory and imaging data, but 8.6% of the cohort had a diagnostic code indicating cirrhosis. Medication use was as follows: antidiabetic drugs (9.2%), antihypertensives (5.1%), non-steroidal anti-inflammatory drugs (NSAIDs) (5.9%) and statins (5.7%). Prevalence of non-HCC neoplasm was 4.7% in the overall cohort.

Data for smoking consumption, alcohol consumption and BMI were available for 71.5%, 56.1% and 61.3% of the cohort (**Table 1**).

Risk factors for HCC included male sex, older age, increased deprivation, Caribbean ethnicity and peptic ulcer disease

Baseline characteristics of the imputed dataset used in analysis of HCC risk factors are presented in **Table 3**. Multivariable Cox proportional hazards models were constructed for 7029 patients in whom 161 HCC cases developed throughout 41 147 person-years of follow-up (**Figure 3, Supplementary Table 8**). This translated to an HCC incidence rate of 5.10 cases per 1000 person-years (95% Confidence Interval (95CIs) 4.46 to 5.84).

Hazards of HCC were increased in males (adjusted hazards ratio (aHR) 3.44, 95% CI 2.07 to 5.73), with increasing age (aHR for 36-45 years 1.96, 95% CI 1.10 to 3.48; aHR for 46-55 years 2.73, 95% CI 1.51 to 4.95; aHR for 56-65 years 3.17, 95% CI 1.63 to 6.14; aHR for ≥66 years 4.06, 95% CI 1.92 to 8.58, as compared to 26-35 years reference group) and in the fifth deprivation quintile as compared to the third quintile (aHR 1.69, 95% CI 1.01 to 2.84). Hazards of HCC in the Caribbean ethnicity

group were higher than those in the White reference group (aHR 3.32, 95% CI 1.43 to 7.71) but did not differ in any other ethnic category. There were no associations between alcohol consumption, cigarette smoking, or BMI with hazards of HCC. As expected, increased hazards of HCC were associated with evidence of advanced liver disease, cirrhosis (aHR 6.52, 95% CI 4.54 to 9.37) and ascites (aHR 1.85, 95% CI 1.02 to 3.36). Interestingly, peptic ulcer disease was also associated with increased HCC hazards (aHR 2.20, 95% CI 1.39 to 3.49). Statin use was associated with reduced hazards of HCC (aHR 0.47, 95% CI 0.22 to 0.99). No other medicines, including antiviral treatment, associated with hazards of HCC.

Hazards ratios did not change materially in strength or direction upon sensitivity analysis excluding non-HCC neoplasms or including AST, ALT and Plt at baseline (**Supplementary Table 8**).

Main model results are robust to complete-case sensitivity analysis

We undertook sensitivity analysis restricted to the subgroup of patients for whom complete data were available (n=3648 patients in whom 68 cases of HCC occurred (**Supplementary Table 9**)). Confidence intervals for all aHRs were more precise in the model from the imputed dataset compared to the complete case analysis due to larger sample size in the former. Hazard ratios did not change materially in strength or direction in sensitivity analysis undertaken to exclude patients with history of non-HCC neoplasms (**Supplementary Table 9**).

DISCUSSION

Summary of key findings

This is the largest cohort of CHB individuals characterised in England to date, from either EHR or traditional prospective cohorts. However, our prevalence estimate of 0.023% contrasts with current U.K. prevalence estimates (0.27% to 0.73%) (41), suggesting many cases of HBV infection are not diagnosed and/or not recorded in primary care records. Substantial efforts are needed in clinical, governance and data domains to enhance diagnosis, linkage to care and information linkage, in order to support better individual patient care and to inform public health programmes.

The CHB population we identified was ethnically diverse, with higher proportions of black and ethnic minority individuals than either the wider QResearch database (42) or the general English population (43). Importantly, the CHB population is disproportionately socioeconomically deprived, with substantial burdens of comorbid disease. This highlights a vulnerable population, for whom specific resources should be targeted to redress health inequities. The QResearch database has geographic coverage across England, and therefore our findings should be generalizable to the wider country, and potentially to other settings. However, we recognise the impacts of selection bias and missingness.

We report increased hazards of HCC associated with increasing age, male sex, socioeconomic deprivation, Caribbean ethnicity, severe liver disease (ascites and cirrhosis), and comorbid disease (peptic ulcer disease). Age, sex and T2DM have previously been found to positively associate with HCC risk in CHB (11), however this is the first cohort study to report these associations in an ethnically diverse cohort. It is likely that we are underpowered to detect associations with alcohol and cigarette consumption with HCC risk in our cohort, although smoking was identified as a risk factor on sensitivity analysis.

It is possible that the positive association of peptic ulcer disease with hazards of HCC is confounded by proton pump inhibitor (PPI) administration for peptic ulcer treatment. Information concerning PPI prescription and usage was not available in our QResearch extract, but previous observational studies have reported increased risks of HCC associated with PPIs (45,46). Pooled risk estimates from meta-analyses have been variable, with some confirming this association (47) and others failing to report associations (48,49), particularly after restricting to studies of participants with viral hepatitis (49).

Influence of HBV genotype

HBV genotype is not routinely determined in clinical practice, so is not available from EHR datasets. Genotype is associated with ethnicity (50,51), and viral genotypes have been associated with both an increased HCC risk (52) and antiviral treatment resistance (53). Therefore, associations of HCC risk with ethnicity and/or socioeconomic status may be driven by HBV genotype. However, the association

may also be mediated by unmeasured population genetic factors and/or other exposures (including lifestyle factors). Increased HCC hazards observed in the most deprived Townsend quintile may similarly be confounded by genotype, however, it is more likely the observed association is mediated by socioeconomic factors whereby access to routine care/surveillance is poorer and additional lifestyle or environmental factors which increase HCC risk are more prevalent.

Drug treatment and HCC development

We report a protective association of statin use with HCC hazards. This association has been reported in previous CHB cohorts (11,54,55), in individuals with predisposing HCC risk factors including cirrhosis and T2DM (56,57) and in a general patient population (55–57). Further analysis, including potential mediation analysis where data availability allows, is warranted to investigate the mechanisms of this association.

We did not find an association of antiviral treatment with reduced HCC risk, although there is evidence from previous observational and randomised interventional studies that CHB treatment with antiviral nucleoside analogues (NAs) reduces HCC risk (58–60). In our sample, 10.3% of individuals initiated antiviral treatment during follow-up. However, a substantial proportion of treatment data may be missing from primary care records, as this information is typically captured in secondary/tertiary care records where HBV prescribing is based (61). For example, 16% of CHB patients in secondary care were receiving antiviral treatment, based on the NIHR Health Informatics Collaborative (HIC) database (62). Our primary care cohort may systematically differ to samples in clinical trials and hospital-based cohorts whereby only a small proportion of individuals are treatment-eligible in our cohort. Additionally, receipt of antiviral treatment may target those with more severe progression/prognosis compared to untreated individuals at baseline, thus negating any signal for a positive effect. Clinical guidelines recommend criteria for treatment, but it is not possible for us to determine the extent to which the 89.7% of patients with no treatment recorded are treatment ineligible, or are receiving treatment in a secondary/tertiary care setting that is not captured in QResearch data. Therefore, the association of antiviral treatment and HCC risk cannot be confidently determined from this dataset.

Application of data to HCC risk stratification

HCC risk scores (including PAGE-B (19), REACH-B (20,21), GAG-HCC (22,23) and CU-HCC (24–26) utilise various characteristics, including age, sex, and laboratory parameters to predict HCC risk. The utility of existing risk scores in homogenous patient subgroups has been demonstrated (63). Our results highlight the need for validation (and potentially modification) of such scores in heterogenous samples which are ethnically and clinically diverse. Identifying groups who carry a significantly higher risk of developing HCC may inform enhanced screening and support early diagnosis. Determination of modifiable risk factors which influence HCC development should inform interventions, for example a risk associated with smoking should inform specific smoking cessation advice and support.

Caveats of primary care EHR analysis – missing data

We highlight substantial data missingness due to poor primary care coverage and HBV representation in such data sources. Missingness likely associated with characteristics not measured in our dataset including thereby excluding marginalised subgroups (including undocumented migrants, highly mobile population subgroups, and people who do not speak English), which may further increase the proportion who fall into the most socioeconomically deprived quintiles.

Most patients were identified by coding, with a minority (3.0%) having confirmatory laboratory tests accessible in QResearch. This is unsurprising given that specialist referral is recommended following a positive test result (64) thus second confirmatory HBV lab data (VL and/or HBsAg) would typically be performed in a secondary or tertiary care centre, and these results are not reliably transferred into primary care EHR systems. Efforts to enhance linkage of data between primary and secondary care would be of significant benefit to patient care, and potentially increase the chance of timely diagnosis of liver complications, including HCC, in patients presenting to their primary care practitioner with early symptoms.

Length of follow-up is shorter than anticipated for a chronic disease despite a 20-year study period from 1999 to 2019. This is not uncommon in EHR databases in which there may be time lags between notification of a patient characteristic/disease and

input into electronic record systems. Additionally, given the neglected nature of CHB, it is likely that individuals present to primary care late in the infection course and/or diagnoses are primarily managed in secondary/tertiary services without linkage to primary care records. Follow-up was differential between individuals who did and did not develop HCC, with shorter median follow-up duration in HCC cases. This may be due to HCC cases only presenting to a GP practice when their liver disease has progressed to a symptomatic, more advanced stage.

Analytical corrections for missing data

We have undertaken imputation of missing baseline data, in line with previous investigations in QResearch (34–37), but were unable to impute important HBV biomarkers (including VL and HBsAg) as >90% of participants were missing any measurement at baseline. We therefore excluded these variables from analysis. High missingness was observed for additional biomarkers, specifically AST, ALT and Plt, which serve as indicators of liver function and can be used to derive proxy scores for staging fibrosis and cirrhosis. Replication of our present analysis in secondary care datasets is a future opportunity to investigate the utility of these biomarkers as markers of disease endpoints. Similarly, we were unable to time-update our models for changes in alcohol and cigarette consumption throughout follow-up due to lack of repeated measurements (>90% of the cohort had a one-off record for alcohol and smoking). Due to missing data, we were also unable to validate and/or modify such scores. Future investigation in data sources where variables are more complete and remeasurement is more comprehensive is warranted to enable these analytical improvements, and allow for more precise estimation of effect sizes.

Characterisation of comorbid or end-organ disease in primary care EHR data sources is also limited due to missing information. For example, cirrhosis is inferred via biopsy, hepatic imaging or laboratory scores (65). However, these data are usually collected in secondary/tertiary care and are not reliably transferred into primary care EHRs. Although we identified a subset of individuals with a diagnostic code indicative of cirrhosis, cirrhotic prevalence in CHB was likely underestimated, and due to this missingness we were unable to investigate risk factors for cirrhosis as an endpoint. Similarly, the prevalence of comorbidities, including renal and cerebrovascular disease, is likely underestimated for this reason, and we are

underpowered to detect associations with HCC risk. A high proportion of data on alcohol consumption is missing, and where alcohol intake is recorded, this may not be reliable. Although alcohol may be a relevant risk factor for HCC development, we are unable to report this association in our study.

Conclusions

The CHB population in the England is ethnically diverse and socioeconomically deprived. We have identified risk factors for HCC, and validated associations observed previously in different CHB populations. Future analysis warrants validation and/or modification of existing CHB-HCC risk scores in diverse patient samples. This may require establishment of a prospective cohort study with long-term follow-up of CHB-individuals sampled from a diverse population. Missingness in various data fields an important observation: it is a limitation both for identification of individuals with CHB, and for robust description of those individuals whose diagnosis is recorded. Enhanced capture of such data is crucial to provide an evidence base for interventions, including diagnostic screening, treatment and surveillance, modification of risk factors for HCC, and monitoring progress towards elimination targets.

ACKNOWLEDGEMENTS

We would like to thank Professor Julia Hippisley-Cox and Rebekah Burrow in the Nuffield Department of Primary Care Health Sciences at the University of Oxford for their founding/direction of and facilitation of access to the QResearch database (respectively), and for their helpful feedback on analysis. We acknowledge the contribution of EMIS practices who contribute to QResearch® and EMIS Health and the Chancellor Masters & Scholars of the University of Oxford for expertise in establishing, developing and supporting the QResearch database. QRESEARCH® is a registered trademark of Egton Medical Information Systems Limited and the University of Nottingham. This project involves data derived from patient-level information collected by the NHS, as part of the care and support of cancer patients. The data is collated, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of Public Health England (PHE). Access to the data was facilitated by the PHE Office for Data Release. This publication is based on data derived from the Intensive Care National Audit & Research Centre (ICNARC) Case Mix Programme Database. The Case Mix

Programme is the national, comparative audit of patient outcomes from adult critical care coordinated by ICNARC. We thank all the staff in the critical care units participating in the Case Mix Programme. For more information on the representativeness and quality of these data, please contact ICNARC. Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of ICNARC. The Office of National Statistics, Public Health England and NHS Digital bear no responsibility for the analysis or interpretation of the data.

CONFLICTS OF INTEREST

IAG is a full-time GSK employee and holds GSK shares. CC's doctoral project is jointly funded by the Nuffield Department of Medicine, University of Oxford and by GSK.

Accessibility of protocol, raw data, and programming code

Further details regarding the study protocol are available on the study webpage (27), and a full protocol can be made available upon request to the corresponding author. Researchers interested in utilising raw QResearch data are encouraged to seek further guidance on the QResearch webpage (66). Programming code can be made available upon request to the corresponding author.

TABLES

Table 1: Cohort baseline characteristics

Characteristic	Total, n (%)	HCC cases, n (%)	Non-HCC cases, n (%)
N	8039	210	7829
Follow-up time (years), median (IQR)	3.87 (6.30)	1.47 (5.13)	3.93 (6.28)
CHB diagnosis source, n (%) *			
Any ICD	3952 (49.2%)	47 (22.4%)	3789 (48.4%)
Any SNOMED/Read	4425 (55.0%)	68 (32.4%)	4357 (55.7%)
Any laboratory test	240 (3.0%)	<5	238 (3.0%)
Age (years), mean (SD)	38.3 (11.6)	50.3 (12.4)	37.9 (11.4)
Age group, n (%)			
18-25 years	860 (10.7%)	<5	857 (10.9%)
26-35 years	2930 (36.4%)	22 (10.5%)	2908 (37.1%)
36-45 years	2346 (29.2%)	52 (24.8%)	2294 (29.3%)
46-55 years	1182 (14.7%)	63 (30.0%)	1119 (14.3%)
56-65 years	502 (6.2%)	41 (19.5%)	461 (5.9%)
≥66 years	219 (2.7%)	29 (13.8%)	190 (2.4%)
Sex, n (%)			
Female	3183 (39.6%)	24 (11.4%)	3159 (40.3%)
Male	4856 (60.4%)	186 (88.6%)	4670 (59.7%)
Townsend Deprivation Quintile, n (%)			
First (least deprived)	467 (5.8%)	27 (12.9%)	440 (5.6%)
Second	731 (9.1%)	20 (9.5%)	711 (9.1%)
Third	1226 (15.3%)	27 (12.9%)	1199 (15.3%)
Fourth	2040 (25.4%)	48 (22.9%)	1992 (25.4%)
Fifth (most deprived)	3553 (44.3%)	87 (41.4%)	3466 (44.3%)
Missing	22 (0.3%)	<5	21 (0.3%)

Characteristic	Total, n (%)	HCC cases, n (%)	Non-HCC cases, n (%)
Ethnicity, n (%)			
Black African	1714 (25.4%)	35 (22.3%)	1679 (25.5%)
Bangladeshi	325 (4.8%)	11 (7.0%)	314 (4.8%)
Caribbean	104 (1.5%)	7 (4.5%)	97 (1.5%)
Chinese	871 (12.9%)	21 (13.4%)	850 (12.9%)
Indian	203 (3.0%)	7 (4.5%)	196 (3.0%)
Other	832 (12.3%)	15 (9.6%)	817 (12.4%)
Other Asian	384 (5.7%)	5 (3.2%)	379 (5.7%)
Pakistani	401 (5.9%)	7 (4.5%)	394 (6.0%)
White	1916 (28.4%)	49 (31.2%)	1867 (28.3%)
Missing	1289 (16.0%)	53 (25.2%)	1236 (15.8%)
Cigarette consumption, n (%)			
Non-smoker	3810 (66.2%)	78 (54.2%)	3732 (66.5%)
Ex-smoker	768 (13.4%)	25 (17.4%)	743 (13.2%)
Light smoker (1-9 cigarettes/day)	908 (15.8%)	31 (21.5%)	877 (15.6%)
Moderate to heavy smoker (≥ 10 cigarettes per day)	266 (4.6%)	10 (6.9%)	256 (4.6%)
Missing	2287 (28.5%)	66 (31.4%)	2221 (28.4%)
Alcohol consumption, n (%)			
Non-drinker	3697 (81.9%)	100 (83.3%)	3597 (81.9%)
Trivial drinker (<1 unit per day)	485 (10.7%)	13 (10.8%)	472 (10.7%)
Light drinker (1-2 units per day)	209 (4.6%)	<5	206 (4.7%)
Moderate to heavy drinker (≥ 3 units per day)	121 (2.7%)	<5	117 (2.7%)

Characteristic	Total, n (%)	HCC cases, n (%)	Non-HCC cases, n (%)
Missing	3527 (43.9%)	90 (42.9%)	3439 (43.9%)
BMI (kg/m ²), mean (SD)	26.05 (5.06)	26.13 (4.63)	26.05 (5.07)
BMI, n (%)			
Underweight (<18.5 kg/m ²)	159 (3.2%)	<5	156 (3.2%)
Normal weight (18.5-24.9 kg/m ²)	2092 (42.5%)	49 (39.8%)	2043 (42.5%)
Overweight (25.0-29.9 kg/m ²)	1734 (35.2%)	52 (42.3%)	1682 (35.0%)
Obese (≥30 kg/m ²)	943 (19.1%)	19 (15.4%)	924 (19.2%)
Missing	3111 (38.7%)	87 (41.4%)	3024 (38.6%)
Antiviral initiation, n (%)			
No initiation	7076 (88.0%)	140 (66.7%)	6936 (88.6%)
Before CHB diagnosis	138 (1.7%)	11 (5.2%)	127 (1.6%)
Within 1 year of CHB diagnosis	221 (2.7%)	24 (11.4%)	197 (2.5%)
Within 2 years of CHB diagnosis	120 (1.5%)	7 (3.3%)	113 (1.4%)
Within 3 years of CHB diagnosis	78 (1.0%)	7 (3.3%)	71 (0.9%)
≥4 years after CHB diagnosis	406 (5.1%)	21 (10.0%)	385 (4.9%)
Type 2 DM, n (%)	715 (8.9%)	21 (10.0%)	664 (8.5%)
Congestive heart failure, n (%)	75 (0.9%)	7 (3.3%)	68 (0.9%)
Hypertension, n (%)	1229 (15.3%)	71 (33.8%)	1158 (14.8%)
Chronic kidney disease, n (%)	287 (3.6%)	29 (13.8%)	258 (3.3%)
Alcohol-related liver	93 (1.2%)	19 (9.0%)	74 (0.9%)

Characteristic	Total, n (%)	HCC cases, n (%)	Non-HCC cases, n (%)
disease, n (%)			
Ascites, n (%)	114 (1.4%)	32 (15.2%)	82 (1.0%)
Autoimmune hepatitis, n (%)	9 (0.1%)	<5	9 (0.1%)
Cerebrovascular disease, n (%)	310 (3.9%)	21 (10.0%)	289 (3.7%)
Cirrhosis, n (%)	689 (8.6%)	121 (57.6%)	568 (7.3%)
End-stage liver disease, n (%)	85 (1.1%)	16 (7.6%)	69 (0.9%)
Ischaemic heart disease, n (%)	255 (3.2%)	20 (9.5%)	235 (3.0%)
Non-alcoholic fatty liver disease, n (%)	404 (5.0%)	8 (3.8%)	396 (5.1%)
Non-HCC neoplasm, n (%)	381 (4.7%)	345 (4.4%)	36 (17.1%)
Peptic ulcer, n (%)	248 (3.1%)	32 (15.2%)	216 (2.8%)
Antidiabetic drug use, n (%)	737 (9.2%)	49 (23.3%)	688 (8.8%)
Antihypertensive use, n (%)	408 (5.1%)	22 (10.5%)	386 (4.9%)
NSAID use, n (%)	472 (5.9%)	24 (11.4%)	448 (5.7%)
Statin use, n (%)	457 (5.7%)	19 (9.0%)	438 (5.6%)

CHB, chronic hepatitis B virus infection; ICD, International classification of disease; SNOMED, Systemised Nomenclature of Medicine; SD, standard deviation; BMI, body mass index; DM, diabetes mellitus; HCC, hepatocellular carcinoma; NSAID, non-steroidal anti-inflammatory drug.

* Some patients have diagnostic indicators of CHB from multiple sources and therefore there overlap between categories.

Table 2. Characteristics of adults with chronic hepatitis B virus infection identified from QResearch primary care database, stratified by socioeconomic status.

Characteristic	Townsend Deprivation Quintile						P
	First (least deprived)	Second	Third	Fourth	Fifth (most deprived)	Missing	
N	467	731	1226	2040	3553	22	
Follow-up time (years), mean (SD)	6.33 (6.59)	6.15 (7.65)	5.40 (5.48)	4.94 (5.25)	5.10 (5.20)	3.79 (3.56)	<0.001
HCC cases, n (%)	27 (5.8%)	20 (2.7%)	27 (2.2%)	48 (2.4%)	87 (2.4%)	<5	0.001
Age (years), mean (SD)	43.64 (13.10)	40.11 (12.26)	38.98 (11.91)	37.35 (11.22)	37.45 (11.08)	38.18 (9.52)	<0.001
Age group, n (%)							<0.001
18-25 years	110 (23.6%)	247 (33.8%)	433 (35.3%)	799 (39.2%)	1330 (37.4%)	11 (50.0%)	
26-35 years	25 (5.4%)	64 (8.8%)	112 (9.1%)	244 (12.0%)	415 (11.7%)	<5	
36-45 years	153 (32.8%)	207 (28.3%)	379 (30.9%)	561 (27.5%)	1041 (29.3%)	5 (22.7%)	
46-55 years	86 (18.4%)	124 (17.0%)	178 (14.5%)	281 (13.8%)	509 (14.3%)	<5	
56-65 years	58 (12.4%)	64 (8.8%)	76 (6.2%)	116 (5.7%)	186 (5.2%)	<5	
≥66 years	35 (7.5%)	25 (3.4%)	48 (3.9%)	39 (1.9%)	72 (2.0%)	<5	
Sex, n (%)							0.021
Female	214 (45.8%)	300 (41.0%)	505 (41.2%)	802 (39.3%)	1355 (38.1%)	7 (31.8%)	
Male	253 (54.2%)	431 (59.0%)	721 (58.8%)	1238 (60.7%)	2198 (61.9%)	15 (68.2%)	
Ethnicity, n (%)							<0.001
Black African	26 (7.2%)	69 (11.9%)	155 (15.8%)	386 (22.5%)	1073 (34.6%)	≤5	
Bangladeshi	<5	10 (1.7%)	26 (2.6%)	56 (3.3%)	229 (7.4%)	<5	
Caribbean	<5	<5	14 (1.4%)	35 (2.0%)	49 (1.6%)	<5	
Chinese	84 (23.3%)	121 (20.9%)	156 (15.9%)	201 (11.7%)	305 (9.8%)	<5	
Indian	10 (2.8%)	17 (2.9%)	55 (5.6%)	80 (4.7%)	40 (1.3%)	<5	
Other	49 (13.6%)	58 (10.0%)	93 (9.5%)	216 (12.6%)	415 (13.4%)	<5	
Other Asian	24 (6.7%)	46 (7.9%)	67 (6.8%)	99 (5.8%)	147 (4.7%)	<5	
Pakistani	19 (5.3%)	41 (7.1%)	98 (10.0%)	153 (8.9%)	90 (2.9%)	<5	
White	143 (39.7%)	213 (36.8%)	318 (32.4%)	486 (28.4%)	755 (24.3%)	<5	
Cigarette consumption,							0.04

n (%)							
Non-smoker	211 (67.8%)	326 (66.3%)	581 (66.3%)	978 (66.4%)	1704 (65.9%)	10 (66.7%)	
Ex-smoker	51 (16.4%)	84 (17.1%)	122 (13.9%)	167 (11.3%)	343 (13.3%)	<5	
Light smoker (1-9 cigarettes/day)	37 (11.9%)	62 (12.6%)	132 (15.1%)	248 (16.8%)	425 (16.4%)	<5	
Moderate to heavy smoker (≥ 10 cigarettes per day)	12 (3.9%)	20 (4.1%)	41 (4.7%)	80 (5.4%)	113 (4.4%)	<5	
Alcohol consumption, n (%)							<0.001
Non-drinker	183 (81.0%)	263 (76.9%)	553 (82.2%)	959 (82.9%)	1732 (82.3%)	7 (70.0%)	
Trivial drinker (<1 unit per day)	32 (14.2%)	42 (12.3%)	70 (10.4%)	120 (10.4%)	221 (10.5%)	<5	
Light drinker (1-2 units per day)	<5	21 (6.1%)	31 (4.6%)	39 (3.4%)	113 (5.4%)	<5	
Moderate to heavy drinker (≥ 3 units per day)	8 (3.5%)	16 (4.7%)	19 (2.8%)	39 (3.4%)	38 (1.8%)	<5	
BMI (kg/m ²), mean (SD)	25.34 (4.76)	25.72 (4.92)	25.81 (4.94)	26.30 (5.31)	26.14 (5.01)	26.56 (4.47)	0.031
BMI, n (%)							0.433
Underweight (<18.5 kg/m ²)	11 (4.3%)	13 (3.2%)	27 (3.7%)	38 (3.0%)	70 (3.1%)	<5	
Normal weight (18.5-24.9 kg/m ²)	125 (48.6%)	176 (43.2%)	322 (43.6%)	533 (42.3%)	933 (41.4%)	<5	
Overweight (25.0-29.9 kg/m ²)	79 (30.7%)	146 (35.9%)	260 (35.2%)	422 (33.5%)	822 (36.5%)	5 (50.0%)	
Obese (≥ 30 kg/m ²)	42 (16.3%)	72 (17.7%)	129 (17.5%)	268 (21.3%)	430 (19.1%)	<5	
Antiviral initiation, n (%)							0.445
No initiation	393 (84.2%)	647 (88.5%)	1071 (87.4%)	1808 (88.6%)	3138 (88.3%)	19 (86.4%)	
Before CHB diagnosis	13 (2.8%)	17 (2.3%)	24 (2.0%)	32 (1.6%)	52 (1.5%)	<5	
Within 1 year of CHB diagnosis	19 (4.1%)	16 (2.2%)	39 (3.2%)	46 (2.3%)	100 (2.8%)	<5	

Within 2 years of CHB diagnosis	7 (1.5%)	9 (1.2%)	14 (1.1%)	29 (1.4%)	61 (1.7%)	<5	
Within 3 years of CHB diagnosis	7 (1.5%)	6 (0.8%)	15 (1.2%)	21 (1.0%)	28 (0.8%)	<5	
≥4 years after CHB diagnosis	28 (6.0%)	36 (4.9%)	63 (5.1%)	104 (5.1%)	17,4 (4.9%)	<5	
Type 2 DM, n (%)	39 (8.4%)	51 (7.0%)	119 (9.7%)	180 (8.8%)	323 (9.1%)	<5	0.383
Congestive heart failure, n (%)	6 (1.3%)	10 (1.4%)	12 (1.0%)	19 (0.9%)	28 (0.8%)	<5	0.675
Hypertension, n (%)	85 (18.2%)	97 (13.3%)	183 (14.9%)	298 (14.6%)	563 (15.8%)	<5	0.212
Chronic kidney disease, n (%)	20 (4.3%)	21 (2.9%)	46 (3.8%)	75 (3.7%)	123 (3.5%)	<5	0.553
Alcohol-related liver disease, n (%)	10 (2.1%)	7 (1.0%)	13 (1.1%)	27 (1.3%)	36 (1.0%)	<5	0.336
Ascites, n (%)	12 (2.6%)	10 (1.4%)	20 (1.6%)	24 (1.2%)	47 (1.3%)	<5	0.188
Autoimmune hepatitis, n (%)	<5	<5	<5	<5	<5	<5	NA
Cerebrovascular disease, n (%)	30 (6.4%)	29 (4.0%)	54 (4.4%)	74 (3.6%)	123 (3.5%)	<5	0.035
End-stage liver disease, n (%)	8 (1.7%)	6 (0.8%)	12 (1.0%)	22 (1.1%)	36 (1.0%)	<5	0.414
Ischaemic heart disease, n (%)	20 (4.3%)	29 (4.0%)	41 (3.3%)	67 (3.3%)	98 (2.8%)	<5	0.28
Non-alcoholic fatty liver disease, n (%)	22 (4.7%)	33 (4.5%)	65 (5.3%)	96 (4.7%)	188 (5.3%)	<5	0.728
Non-HCC neoplasm, n (%)	132 (28.3%)	161 (22.0%)	272 (22.2%)	359 (17.6%)	699 (19.7%)	<5	<0.001
Peptic ulcer, n (%)	26 (5.6%)	13 (1.8%)	43 (3.5%)	58 (2.8%)	108 (3.0%)	<5	0.008
Antidiabetic drug use, n (%)	41 (8.8%)	54 (7.4%)	125 (10.2%)	183 (9.0%)	330 (9.3%)	<5	0.242
Antihypertensive use, n (%)	25 (5.4%)	36 (4.9%)	66 (5.4%)	107 (5.2%)	174 (4.9%)	<5	0.865

NSAID use, n (%)	26 (5.6%)	29 (4.0%)	86 (7.0%)	112 (5.5%)	217 (6.1%)	<5	0.106
Statin use, n (%)	21 (4.5%)	30 (4.1%)	78 (6.4%)	114 (5.6%)	213 (6.0%)	<5	0.268

CHB, chronic hepatitis B virus infection; ICD, International classification of disease; SNOMED, Systemised Nomenclature of Medicine; SD, standard deviation; BMI, body mass index; DM, diabetes mellitus; HCC, hepatocellular carcinoma; NSAID, non-steroidal anti-inflammatory drug.

Table 3. Baseline characteristics of complete-case and imputed (by multiple imputation with chained equations) datasets used in Cox proportional hazards models.

Characteristic	Complete-case dataset, n (%)	Imputed dataset, n (%)
N	3648	7029*
HCC cases, n (%)	68 (1.9%)	161 (2.3%)
Age group, n (%)		
18-25 years	292 (8.0)	659 (9.4)
26-35 years	1253 (34.3)	2500 (35.6)
36-45 years	1126 (30.9)	2108 (30.0)
46-55 years	593 (16.3)	1086 (15.5)
56-65 years	270 (7.4)	468 (6.7)
≥66 years	114 (3.1)	208 (3.0)
Sex, n (%)		
Male	2082 (57.1)	4186 (59.6)
Townsend Deprivation Quintile, n (%)		
First (least deprived)	174 (4.8)	419 (6.0)
Second	261 (7.2)	645 (9.2)
Third	523 (14.3)	1094 (15.6)
Fourth	924 (25.3)	1781 (25.3)
Fifth (most deprived)	1766 (48.4)	3090 (44.0)
Ethnicity, n (%)		
Black African	956 (26.2)	1772 (25.2)
Bangladeshi	213 (5.8)	322 (4.6)
Caribbean	58 (1.6)	112 (1.6)
Chinese	428 (11.7)	894 (12.7)
Indian	131 (3.6)	224 (3.2)
Other	441 (12.1)	863 (12.3)
Other Asian	194 (5.3)	397 (5.6)
Pakistani	241 (6.6)	420 (6.0)

Characteristic	Complete-case dataset, n (%)	Imputed dataset, n (%)
White	986 (27.0)	2025 (28.8)
Cigarette consumption, n (%)		
Non-smoker	2484 (68.1)	4661 (66.3)
Ex-smoker	480 (13.2)	924 (13.1)
Light smoker (1-9 cigarettes/day)	531 (14.6)	1110 (15.8)
Moderate to heavy smoker (≥ 10 cigarettes per day)	153 (4.2)	334 (4.8)
Alcohol consumption, n (%)		
Non-drinker	3013 (82.6)	5784 (82.3)
Trivial drinker (<1 unit per day)	371 (10.2)	737 (10.5)
Light drinker (1-2 units per day)	170 (4.7)	318 (4.5)
Moderate to heavy drinker (≥ 3 units per day)	94 (2.6)	190 (2.7)
BMI (kg/m^2), mean (SD)	26.14 (5.07)	26.05 (5.02)
BMI, n (%)		
Underweight (<18.5 kg/m^2)	113 (3.1)	222 (3.2)
Normal weight (18.5-24.9 kg/m^2)	1530 (41.9)	2948 (41.9)
Overweight (25.0-29.9 kg/m^2)	1292 (35.4)	2527 (36.0)
Obese (≥ 30 kg/m^2)	713 (19.5)	1332 (19.0)
Antiviral initiation, n (%)		
No initiation	3168 (86.8)	6092 (86.7)
Before CHB diagnosis	67 (1.8)	121 (1.7)

Characteristic	Complete-case dataset, n (%)	Imputed dataset, n (%)
Within 1 year of CHB diagnosis	116 (3.2)	214 (3.0)
Within 2 years of CHB diagnosis	73 (2.0)	120 (1.7)
Within 3 years of CHB diagnosis	49 (1.3)	78 (1.1)
≥4 years after CHB diagnosis	175 (4.8)	404 (5.7)
Type 2 DM, n (%)	503 (13.8)	678 (9.6)
Congestive heart failure, n (%)	41 (1.1)	71 (1.0)
Hypertension, n (%)	754 (20.7)	1165 (16.6)
Chronic kidney disease, n (%)	175 (4.8)	271 (3.9)
Alcohol-related liver disease, n (%)	39 (1.1)	74 (1.1)
Ascites, n (%)	34 (0.9)	88 (1.3)
Autoimmune hepatitis, n (%)	3 (0.1)	9 (0.1)
Cerebrovascular disease, n (%)	181 (5.0)	290 (4.1)
Cirrhosis, n (%)	301 (8.3)	608 (8.6)
End-stage liver disease, n (%)	28 (0.8)	78 (1.1)
Ischaemic heart disease, n (%)	143 (3.9)	229 (3.3)
Non-alcoholic fatty liver disease, n (%)	248 (6.8)	393 (5.6)
Non-HCC neoplasm, n (%)	167 (4.6)	340 (4.8)
Peptic ulcer, n (%)	113 (3.1)	221 (3.1)
Antidiabetic drug use, n (%)	495 (13.6)	689 (9.8)
Antihypertensive use, n (%)	293 (8.0)	389 (5.5)

Characteristic	Complete-case dataset, n (%)	Imputed dataset, n (%)
NSAID use, n (%)	331 (9.1)	446 (6.3)
Statin use, n (%)	342 (9.4)	443 (6.3)

CHB, chronic hepatitis B virus infection; ICD, International classification of disease; SNOMED, Systemised Nomenclature of Medicine; IQR, interquartile range; SD, standard deviation; BMI, body mass index; DM, diabetes mellitus; HCC, hepatocellular carcinoma; NSAID, non-steroidal anti-inflammatory drug.

Figures




Figure 1. Townsend deprivation quintile breakdown in 8039 adults with chronic hepatitis B virus infection derived from the QResearch primary care database (England) versus the United Kingdom general population.





Figure 2. Ethnicity breakdown in 8039 adults in a chronic hepatitis B virus cohort characterised from the QResearch primary care database (England) versus all individuals in the QResearch database (~35 million), vs. the United Kingdom general population. General population estimates obtained from 2019 estimates from the Office for National Statistics.



Blomarker

Adjusted HR

Adjusted HR




Figure 3. Forest plot for Cox proportional hazards model to identify risks of hepatocellular carcinoma (HCC) in an adult population with chronic Hepatitis B virus infection derived from the QResearch primary care database. Analysed using a dataset generated by multiple imputation with chained equations (n = 7029, HCC cases = 161). First (least deprived) to fifth (most deprived) Townsend Deprivation Quintiles are denoted by SES1-5, respectively.

1

2 **References**

- 3 1. Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et
4 al. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic
5 analysis for the Global Burden of Disease Study 2019. *Lancet Gastroenterol Hepatol*
6 [Internet]. 2022 Jun 1 [cited 2022 Aug 10];7(9):796–829. Available from:
7 <http://www.thelancet.com/article/S2468125322001248/fulltext>
- 8 2. Fitzmaurice C, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The
9 burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the
10 global, regional, and national level results from the global burden of disease study
11 2015. *JAMA Oncol*. 2017 Dec 1;3(12):1683–91.
- 12 3. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The
13 global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of
14 Disease Study 2013. *The Lancet*. 2016 Sep 10;388(10049):1081–8.
- 15 4. World Health Organization. Global Health Sector Strategies on viral hepatitis 2016–21.
16 2016.
- 17 5. DeLIVER: Early detection of hepatocellular liver cancer — OxCODE [Internet]. [cited
18 2022 Aug 11]. Available from: [https://www.oxcode.ox.ac.uk/research-showcase/liver-](https://www.oxcode.ox.ac.uk/research-showcase/liver-cancer)
19 [cancer](https://www.oxcode.ox.ac.uk/research-showcase/liver-cancer)
- 20 6. Campbell C, Wang T, Burrow R, Mandal S, Hippisley-Cox J, Barnes E, et al. Estimating
21 the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we
22 know and what are we missing? *Wellcome Open Research* 2022 7:203 [Internet]. 2022
23 Aug 8 [cited 2022 Aug 10];7:203. Available from:
24 <https://wellcomeopenresearch.org/articles/7-203>
- 25 7. Public Health England. Hepatitis B in the South East: 2016 data [Internet]. 2019 [cited
26 2019 Nov 4]. Available from: www.facebook.com/PublicHealthEngland
- 27 8. Public Health England. Hepatitis B in London: 2016 data [Internet]. 2019 [cited 2019
28 Nov 4]. Available from: www.facebook.com/PublicHealthEngland
- 29 9. Public Health England. Hepatitis B in the South West: 2017 data [Internet]. 2019 [cited
30 2019 Nov 4]. Available from:
31 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach-](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/842049/Hepatitis_B_in_the_South_West_2017_data_3_.pdf)
32 [ment_data/file/842049/Hepatitis_B_in_the_South_West_2017_data_3_.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/842049/Hepatitis_B_in_the_South_West_2017_data_3_.pdf)
- 33 10. Public Health England. Hepatitis B in the West Midlands: 2017 data [Internet]. 2019
34 [cited 2019 Nov 4]. Available from: www.facebook.com/PublicHealthEngland
- 35 11. Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Risk factors for the
36 development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV)
37 infection: a systematic review and meta-analysis. *J Viral Hepat* [Internet]. 2021 Mar 1
38 [cited 2022 Mar 3];28(3):493–507. Available from:
39 <https://onlinelibrary.wiley.com/doi/full/10.1111/jvh.13452>
- 40 12. Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Illoeje UH, et al. Prediction models
41 of long-term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B
42 patients: Risk scores integrating host and virus profiles. *Hepatology* [Internet]. 2013
43 Aug [cited 2020 Jun 8];58(2):546–54. Available from:
44 <https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.26385>
- 45 13. Yang HI, Yuen MF, Chan HLY, Han KH, Chen PJ, Kim DY, et al. Risk estimation for
46 hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and

- 1 validation of a predictive score. *Lancet Oncol* [Internet]. 2011 [cited 2020 Jun
2 8];12(6):568–74. Available from: <https://pubmed.ncbi.nlm.nih.gov/21497551/>
- 3 14. Wong GLH, Wong VWS. Risk prediction of hepatitis B virus-related hepatocellular
4 carcinoma in the era of antiviral therapy. *World J Gastroenterol* [Internet]. 2013 Oct
5 21 [cited 2020 Jun 8];19(39):6515–22. Available from:
6 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801362/>
- 7 15. Yuen MF, Tanaka Y, Fong DYT, Fung J, Wong DKH, Yuen JCH, et al. Independent risk
8 factors and predictive score for the development of hepatocellular carcinoma in
9 chronic hepatitis B. *J Hepatol* [Internet]. 2009 Jan [cited 2020 Jun 8];50(1):80–8.
10 Available from: <https://pubmed.ncbi.nlm.nih.gov/18977053/>
- 11 16. Chan HLY, Hui AY, Wong ML, Tse AML, Hung LCT, Wong VWS, et al. Genotype C
12 hepatitis B virus infection is associated with an increased risk of hepatocellular
13 carcinoma. *Gut* [Internet]. 2004 Oct [cited 2020 Jun 8];53(10):1494–8. Available from:
14 <https://gut.bmj.com/content/53/10/1494>
- 15 17. Chan HLY, Tse CH, Mo F, Koh J, Wong VWS, Wong GLH, et al. High viral load and
16 hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular
17 carcinoma. *Journal of Clinical Oncology* [Internet]. 2008 Jan 10 [cited 2020 Jun
18 8];26(2):177–82. Available from: <https://pubmed.ncbi.nlm.nih.gov/18182659/>
- 19 18. Wong VWS, Chan SL, Mo F, Chan TC, Loong HHF, Wong GLH, et al. Clinical scoring
20 system to predict hepatocellular carcinoma in chronic hepatitis B carriers. *Journal of*
21 *Clinical Oncology* [Internet]. 2010 Apr 1 [cited 2020 Jun 8];28(10):1660–5. Available
22 from: <https://pubmed.ncbi.nlm.nih.gov/20194845/>
- 23 19. Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, et al. PAGE-B
24 predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic
25 hepatitis B on 5-year antiviral therapy. *J Hepatol* [Internet]. 2016 Apr 1 [cited 2022 Jul
26 22];64(4):800–6. Available from: [http://www.journal-of-](http://www.journal-of-hepatology.eu/article/S0168827815007953/fulltext)
27 [hepatology.eu/article/S0168827815007953/fulltext](http://www.journal-of-hepatology.eu/article/S0168827815007953/fulltext)
- 28 20. Yang HI, Yuen MF, Chan HLY, Han KH, Chen PJ, Kim DY, et al. Risk estimation for
29 hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and
30 validation of a predictive score. *Lancet Oncol* [Internet]. 2011 [cited 2022 Jul
31 22];12(6):568–74. Available from: <https://pubmed.ncbi.nlm.nih.gov/21497551/>
- 32 21. Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, et al. Prediction models
33 of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B
34 patients: risk scores integrating host and virus profiles. *Hepatology* [Internet]. 2013
35 Aug [cited 2022 Jul 22];58(2):546–54. Available from:
36 <https://pubmed.ncbi.nlm.nih.gov/23504622/>
- 37 22. Wong GLH, Wong VWS. Risk prediction of hepatitis B virus-related hepatocellular
38 carcinoma in the era of antiviral therapy. *World J Gastroenterol* [Internet]. 2013 Oct
39 21 [cited 2022 Jul 22];19(39):6515–22. Available from:
40 <https://pubmed.ncbi.nlm.nih.gov/24151375/>
- 41 23. Yuen MF, Tanaka Y, Fong DYT, Fung J, Wong DKH, Yuen JCH, et al. Independent risk
42 factors and predictive score for the development of hepatocellular carcinoma in
43 chronic hepatitis B. *J Hepatol* [Internet]. 2009 Jan [cited 2022 Jul 22];50(1):80–8.
44 Available from: <https://pubmed.ncbi.nlm.nih.gov/18977053/>
- 45 24. Chan HLY, Hui AY, Wong ML, Tse AML, Hung LCT, Wong VWS, et al. Genotype C
46 hepatitis B virus infection is associated with an increased risk of hepatocellular

- 1 carcinoma. Gut [Internet]. 2004 Oct [cited 2022 Jul 22];53(10):1494–8. Available from:
2 <https://pubmed.ncbi.nlm.nih.gov/15361502/>
- 3 25. Chan HLY, Tse CH, Mo F, Koh J, Wong VWS, Wong GLH, et al. High viral load and
4 hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular
5 carcinoma. J Clin Oncol [Internet]. 2008 Jan 10 [cited 2022 Jul 22];26(2):177–82.
6 Available from: <https://pubmed.ncbi.nlm.nih.gov/18182659/>
- 7 26. Wong VWS, Chan SL, Mo F, Chan TC, Loong HHF, Wong GLH, et al. Clinical scoring
8 system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol
9 [Internet]. 2010 Apr 1 [cited 2022 Jul 22];28(10):1660–5. Available from:
10 <https://pubmed.ncbi.nlm.nih.gov/20194845/>
- 11 27. Characteristics of Chronic Hepatitis B associated with Cirrhosis and Cancer [Internet].
12 [cited 2020 Aug 18]. Available from: [https://www.qresearch.org/research/approved-](https://www.qresearch.org/research/approved-research-programs-and-projects/characteristics-of-chronic-hepatitis-b-associated-with-cirrhosis-and-cancer/)
13 [research-programs-and-projects/characteristics-of-chronic-hepatitis-b-associated-](https://www.qresearch.org/research/approved-research-programs-and-projects/characteristics-of-chronic-hepatitis-b-associated-with-cirrhosis-and-cancer/)
14 [with-cirrhosis-and-cancer/](https://www.qresearch.org/research/approved-research-programs-and-projects/characteristics-of-chronic-hepatitis-b-associated-with-cirrhosis-and-cancer/)
- 15 28. QResearch Database [Internet]. [cited 2020 Aug 18]. Available from:
16 <https://www.qresearch.org/>
- 17 29. Ferreira G, Stuurman AL, Horsmans Y, Cattaert T, Verstraeten T, Feng Y, et al. Hepatitis
18 B virus infection and the risk of liver disease progression in type 2 diabetic patients
19 with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort
20 study in the United Kingdom Clinical Practice Research Datalink. Eur J Gastroenterol
21 Hepatol. 2020 Jan 1;32(1):101–9.
- 22 30. List of ethnic groups - GOV.UK [Internet]. [cited 2022 Aug 12]. Available from:
23 [https://www.ethnicity-facts-figures.service.gov.uk/style-guide/ethnic-groups#2001-](https://www.ethnicity-facts-figures.service.gov.uk/style-guide/ethnic-groups#2001-census)
24 [census](https://www.ethnicity-facts-figures.service.gov.uk/style-guide/ethnic-groups#2001-census)
- 25 31. A healthy lifestyle - WHO recommendations [Internet]. [cited 2022 Aug 12]. Available
26 from: [https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle--](https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle--who-recommendations)
27 [-who-recommendations](https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle--who-recommendations)
- 28 32. Summary Analysis of Linked Cancer Data - QResearch [Internet]. [cited 2022 Feb 6].
29 Available from: [https://www.qresearch.org/data/summary-analysis-of-linked-cancer-](https://www.qresearch.org/data/summary-analysis-of-linked-cancer-data/)
30 [data/](https://www.qresearch.org/data/summary-analysis-of-linked-cancer-data/)
- 31 33. Data - QResearch [Internet]. [cited 2022 Feb 6]. Available from:
32 <https://www.qresearch.org/data/>
- 33 34. Saatci D, Ranger TA, Garriga C, Clift AK, Zaccardi F, Tan PS, et al. Association Between
34 Race and COVID-19 Outcomes Among 2.6 Million Children in England. JAMA Pediatr
35 [Internet]. 2021 Sep 1 [cited 2022 Feb 6];175(9):928–38. Available from:
36 <https://jamanetwork.com/journals/jamapediatrics/fullarticle/2780966>
- 37 35. Hippisley-Cox J, Young D, Coupland C, Channon KM, Tan PS, Harrison DA, et al. Risk of
38 severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers:
39 cohort study including 8.3 million people. Heart [Internet]. 2020 Oct 1 [cited 2022 Feb
40 6];106(19):1503–11. Available from: <https://heart.bmj.com/content/106/19/1503>
- 41 36. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and
42 risk of venous thromboembolism: nested case-control studies using the QResearch
43 and CPRD databases. BMJ [Internet]. 2019 Jan 9 [cited 2022 Feb 6];364:4810.
44 Available from: <https://www.bmj.com/content/364/bmj.k4810>
- 45 37. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and
46 risk of venous thromboembolism: nested case-control studies using the QResearch
47 and CPRD databases. [cited 2022 Feb 6]; Available from: www.cprd.com

- 1 38. van Buuren S. Flexible Imputation of Missing Data. Second Edition. [Internet]. Boca
2 Raton, FL: Chapman & Hall/CRC. ; 2018 [cited 2022 Aug 16]. Available from:
3 <https://stefvanbuuren.name/fimd/>
- 4 39. Rubin DB. Multiple Imputation for Nonresponse in Surveys [Internet]. 1st ed. Vol. 1.
5 Cambridge, Massachusetts: John Wiley & Sons, Ltd; 1987 [cited 2022 Feb 6]. i–xxix.
6 Available from:
7 <https://onlinelibrary.wiley.com/doi/full/10.1002/9780470316696.fmatter>
- 8 40. Marshall A, Billingham LJ, Bryan S. Can we afford to ignore missing data in cost-
9 effectiveness analyses? *Eur J Health Econ* [Internet]. 2009 Feb [cited 2022 Feb
10 6];10(1):1–3. Available from: <https://pubmed.ncbi.nlm.nih.gov/18936993/>
- 11 41. Campbell C, Wang T, Burrow R, Mandal S, Hippisley-Cox J, Barnes E, et al. Estimating
12 the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we
13 know and what are we missing? 2022 Apr 13 [cited 2022 Aug 12]; Available from:
14 <https://europepmc.org/article/PPR/PPR482357>
- 15 42. Summary of GP population characteristics - QResearch [Internet]. [cited 2022 Jul 19].
16 Available from: [https://www.qresearch.org/data/summary-of-gp-population-
17 characteristics/](https://www.qresearch.org/data/summary-of-gp-population-characteristics/)
- 18 43. Population estimates by ethnic group, England and Wales - Office for National
19 Statistics [Internet]. [cited 2022 Jul 19]. Available from:
20 [https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity/
21 datasets/populationestimatesbyethnicgroupenglandandwales](https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity/datasets/populationestimatesbyethnicgroupenglandandwales)
- 22 44. Hippisley-Cox J, Coupland C, Brindle P. The performance of seven QPrediction risk
23 scores in an independent external sample of patients from general practice: a
24 validation study. *BMJ Open* [Internet]. 2014 Aug 1 [cited 2022 Aug 12];4(8):e005809.
25 Available from: <https://bmjopen.bmj.com/content/4/8/e005809>
- 26 45. Shao YHJ, Chan TS, Tsai K, Wu SY. Association between proton pump inhibitors and
27 the risk of hepatocellular carcinoma. *Aliment Pharmacol Ther* [Internet]. 2018 Aug 1
28 [cited 2022 Jul 20];48(4):460–8. Available from:
29 <https://onlinelibrary.wiley.com/doi/full/10.1111/apt.14835>
- 30 46. Kim S, Jeong S, Park SJ, Chang J, Choi S, Cho Y, et al. Association between Proton Pump
31 Inhibitor Use and Risk of Hepatocellular Carcinoma: A Korean Nationally
32 Representative Cohort Study. *Journal of Clinical Medicine* 2022, Vol 11, Page 2865
33 [Internet]. 2022 May 19 [cited 2022 Jul 20];11(10):2865. Available from:
34 <https://www.mdpi.com/2077-0383/11/10/2865/htm>
- 35 47. Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver
36 cancer and mortality in patients with chronic liver disease: a systematic review and
37 meta-analysis. *European Journal of Clinical Pharmacology* 2020 76:6 [Internet]. 2020
38 Mar 14 [cited 2022 Jul 20];76(6):851–66. Available from:
39 <https://link.springer.com/article/10.1007/s00228-020-02854-8>
- 40 48. Wang J, Wu Y, Bi Q, Zheng X, Zhang J, Huang W. Adverse outcomes of proton pump
41 inhibitors in chronic liver disease: a systematic review and meta-analysis. *Hepatology*
42 *International* 2020 14:3 [Internet]. 2020 Jan 7 [cited 2022 Jul 20];14(3):385–98.
43 Available from: <https://link.springer.com/article/10.1007/s12072-019-10010-3>
- 44 49. Kao WY, Su CW, Chia-Hui Tan E, Lee PC, Chen PH, Tang JH, et al. Proton Pump
45 Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or
46 C. *Hepatology* [Internet]. 2019 Mar 1 [cited 2022 Jul 20];69(3):1151–64. Available
47 from: <https://onlinelibrary.wiley.com/doi/full/10.1002/hep.30247>

- 1 50. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances.
2 J Gastroenterol Hepatol [Internet]. 2011 [cited 2022 Jul 22];26(SUPPL. 1):123–30.
3 Available from: [https://onlinelibrary.wiley.com/doi/full/10.1111/j.1440-](https://onlinelibrary.wiley.com/doi/full/10.1111/j.1440-1746.2010.06541.x)
4 [1746.2010.06541.x](https://onlinelibrary.wiley.com/doi/full/10.1111/j.1440-1746.2010.06541.x)
- 5 51. Lin CL, Kao JH. Hepatitis B Virus Genotypes and Variants. Cold Spring Harb Perspect
6 Med [Internet]. 2015 May 1 [cited 2022 Jul 22];5(5):a021436. Available from:
7 <http://perspectivesinmedicine.cshlp.org/content/5/5/a021436.full>
- 8 52. Wong GLH, Chan HLY, Yiu KKL, Lai JWY, Chan VKK, Cheung KKC, et al. Meta-analysis:
9 the association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment
10 Pharmacol Ther [Internet]. 2013 Mar 1 [cited 2022 Jul 22];37(5):517–26. Available
11 from: <https://onlinelibrary.wiley.com/doi/full/10.1111/apt.12207>
- 12 53. Araujo NM, Teles SA, Spitz N. Comprehensive Analysis of Clinically Significant Hepatitis
13 B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region.
14 Front Microbiol. 2020 Dec 14;11:3241.
- 15 54. Goh MJ, Sinn DH, Kim S, Woo SY, Cho H, Kang W, et al. Statin Use and the Risk of
16 Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Hepatology [Internet].
17 2020 Jun 1 [cited 2022 Jul 22];71(6):2023–32. Available from:
18 <https://onlinelibrary.wiley.com/doi/full/10.1002/hep.30973>
- 19 55. Facciorusso A, el Aziz MAA, Singh S, Pusceddu S, Milione M, Giacomelli L, et al. Statin
20 Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis.
21 Cancers 2020, Vol 12, Page 874 [Internet]. 2020 Apr 3 [cited 2022 Jul 22];12(4):874.
22 Available from: <https://www.mdpi.com/2072-6694/12/4/874/htm>
- 23 56. Islam MM, Poly TN, Walther BA, Yang HC, Li YC. Statin Use and the Risk of
24 Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies. Cancers 2020,
25 Vol 12, Page 671 [Internet]. 2020 Mar 13 [cited 2022 Jul 22];12(3):671. Available from:
26 <https://www.mdpi.com/2072-6694/12/3/671/htm>
- 27 57. Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma
28 in patients at high risk: A nationwide nested case-control study. J Hepatol. 2018 Mar
29 1;68(3):476–84.
- 30 58. Udompap P, Kim WR. Development of Hepatocellular Carcinoma in Patients With
31 Suppressed Viral Replication: Changes in Risk Over Time. Clin Liver Dis (Hoboken)
32 [Internet]. 2020 Feb 1 [cited 2022 Nov 7];15(2):85. Available from:
33 [/pmc/articles/PMC7098665/](https://pubmed.ncbi.nlm.nih.gov/35767258/)
- 34 59. Huang DQ, Lim SG. Hepatitis B: Who to treat? A critical review of international
35 guidelines. Liver International [Internet]. 2020 Feb 1 [cited 2022 Nov 7];40(S1):5–14.
36 Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/liv.14365>
- 37 60. Tan DJH, Ng CH, Tay PWL, Syn N, Muthiah MD, Lim WH, et al. Risk of Hepatocellular
38 Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A
39 Reconstructed Individual Patient Data Meta-analysis. JAMA Netw Open [Internet].
40 2022 Jun 29 [cited 2022 Nov 7];5(6). Available from:
41 <https://pubmed.ncbi.nlm.nih.gov/35767258/>
- 42 61. Wang T, Smith DA, Campbell C, Freeman O, Moysova Z, Noble T, et al. Cohort Profile:
43 The National Institute for Health Research Health Informatics Collaborative: Hepatitis
44 B Virus (NIHR HIC HBV) research dataset. Int J Epidemiol [Internet]. 2022 Jun 16 [cited
45 2022 Jul 6];2022:1–11. Available from: [https://academic.oup.com/ije/advance-](https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyac127/6609198)
46 [article/doi/10.1093/ije/dyac127/6609198](https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyac127/6609198)

- 1 62. Campbell C, Wang T, Smith DA, Freeman O, Noble T, Várnai KA, et al. Impact of the
2 COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus
3 (HBV) infection in the UK. [cited 2022 Aug 16]; Available from:
4 <https://doi.org/10.1101/2021.11.10.21265651>
- 5 63. Voulgaris T, Papatheodoridi M, Lampertico P, Papatheodoridis G v. Clinical utility of
6 hepatocellular carcinoma risk scores in chronic hepatitis B. *Liver International*
7 [Internet]. 2020 Mar 1 [cited 2022 Aug 17];40(3):484–95. Available from:
8 <https://onlinelibrary.wiley.com/doi/full/10.1111/liv.14334>
- 9 64. National Institute for Health and Care Excellence. Hepatitis B (chronic): diagnosis and
10 management Clinical guideline. 2013 [cited 2022 Jul 20]; Available from:
11 www.nice.org.uk/guidance/cg165
- 12 65. Cirrhosis in over 16s Assessment and management NICE guideline NG50.
- 13 66. Information for Researchers - QResearch [Internet]. [cited 2022 Aug 22]. Available
14 from: <https://www.qresearch.org/information/information-for-researchers/>
15